Recent Transactions

Cayman Islands counsel to Structure Therapeutics Inc., a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, in relation to its US$650 million public offering of ADSs and pre-funded warrants. Lucy Anderson led our team.

Privy Council dismisses appeal against order winding up Aquapoint LP    Travers Thorp Alberga has successfully represented Dr Frank Fan at the Judicial Committee of the Privy Council, which has now confirmed the earlier decisions of Justice Doyle at First instance and the Cayman Islands Court of Appeal that it is just and equitable for Aquapoint LP to be wound up. The Privy Council’s dismissal of the appeal by the general partner of Aquapoint L.P. is the final decision and Dr Fan will after almost 5 years of petitioning, receive his proportionate shares in Legend Biotech Corporation, a NASDAQ listed company with a market cap of over $5bn, in which the Partnership holds approximately $750m worth of stock. The team was led by TTA litigation partner Bhavesh Patel, and consisted of counsel Bryan Little, instructing Ben Valentin KC of Fountain Court with Seladore Legal as Privy Council agents. The JCPC upheld the decision of the Cayman Islands Court of Appeal (which had upheld the decision of Justice Doyle) to wind up Aquapoint LP on just and equitable grounds. TTA’s advisories in respect of the first instance and CICA decisions can be found here.

The decision means that Martin Trott of R&H Restructuring and Tony Kapp of Shinewing can continue their role as liquidators appointed over the Partnership and distribute the shares it holds in Legend Biotech. The JCPC board’s decision can be found at https://www.jcpc.uk/cases/jcpc-2024-0007.

Travers Thorp Alberga acted as Cayman counsel to WeRide Inc (NASDAQ: WRD, HKEX: 0800.HK), a global leader in autonomous driving technology, on its successful HK$2.39bn dual-primary listing on the Main Board of the Hong Kong Stock Exchange. This move marks the first Robotaxi company to be simultaneously listed in both Hong Kong and the US and is a sign of continued growth within the AI-driven transport sector. Richard Thorp and Raymond Ng led the Travers Thorp Alberga team in Hong Kong.

Travers Thorp Alberga acted as Cayman counsel to Mega Fortune Company Limited (NASDAQ: MGRT), an Internet of Things (“IoT”) solution provider, on its successful listing on the Nasdaq Capital Market. This represents a major milestone in the company’s global growth and a key step towards its vision of being the preferred choice for IoT solutions for enterprises and projects in the Asia-Pacific region. Richard Thorp and Raymond Ng led the Travers Thorp Alberga team in Hong Kong.

Travers Thorp Alberga acted as Cayman counsel to CTW Cayman (NASDAQ: CTW), a leading web-based video gaming platform provider, on its successful listing on the Nasdaq Capital Market. This represents a major milestone in the company’s global growth and its continued success in delivering high-quality and animation-themed video gaming experiences to video game players and end-users worldwide. Richard Thorp and Raymond Ng led the Travers Thorp Alberga team in Hong Kong.

Cayman Islands counsel to Structure Therapeutics Inc., a clinical-stage global biopharmaceutical company, in relation to its August 2025 shelf-registration statement and at-the-market offering of up to US$250 million. Lucy Anderson led our team.

Travers Thorp Alberga acted as Cayman counsel to DDC Enterprise Limited (NYSE: DDC) on its US$300m secured convertible note financing arrangements and a US$200m equity line of credit in order to advance its Bitcoin Treasury Strategy. Richard Thorp, James Webb and Raymond Ng led the Travers Thorp Alberga team in Hong Kong.

Cayman Islands counsel to VISEN Pharmaceuticals, an innovative biopharmaceutical company focused on endocrine diseases, in its initial public offering on the Hong Kong Stock Exchange in March 2025. Lucy Anderson led our team.

TTA acted for WeRide in its IPO, after the self-driving startup raised $440.5 million in its IPO and private placement valuing the company at over US$4B, becoming the latest Chinese firm to capitalize on improving market sentiment. The strong performance reflects a growing appetite among U.S. investors for Chinese companies, following nearly two years of uncertainty after the ride-hailing giant Didi Global’s delisting due to regulatory backlash in China.

Cayman Islands counsel to the Buyer Group on the take-private of NYSE-listed TDCX Inc., by way of short-form merger in accordance with section 233(7) of the Companies Act, in a transaction valuing the digital CX solutions provider at approximately US$1.0 billion.

Cayman Islands counsel to Structure Therapeutics Inc., a clinical-stage global biopharmaceutical company, in its upsized public offering in June 2024. Lucy Anderson led our team.

Cayman Islands counsel to ProfoundBio Inc., which was acquired in May 2024 by international biotechnology company Genmab by way of Cayman Islands merger. Lucy Anderson led our team.